ScreenerHero
HIKHikma Pharmaceuticals PLC
LSE · GB · Healthcare · Drug Manufacturers - Specialty & Generic · hikma.com
1636.00GBp+0.74%Mkt Cap: 3.69B $P/E: 12.68

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. Th…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.46BUSDP/E 37.1

Key Statistics

Company
Market Cap3.69B $
Enterprise Value5.65B $
Revenue (TTM)3.72B $
Gross Profit1.57B $
Net Income (TTM)436.96M $
Revenue/Share17.00 USD
Last Price1636.00 GBp
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9.5K
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)12.68
P/E (Forward)8.81
PEG1.71
EV/EBITDA5.92
EV/Revenue1.52
P/S0.98
P/B1.89
EPS (TTM)1.30
EPS (Forward)1.83
52W Range
1187.0066% of range1865.00
52W High1865.00 GBp
52W Low1187.00 GBp
Profitability
Gross Margin43.03%
Oper. Margin23.49%
EBITDA Margin25.71%
Profit Margin12.00%
ROE15.50%
ROA7.09%
Growth
Revenue Growth4.20%
Earnings Growth-4.70%
Cash Flow & Leverage
Operating CF473.91M $
CapEx (TTM)344.57M $
FCF Margin0.42%
FCF Yield0.42%
Net Debt1.81B $
Net Debt/EBITDA1.90
Balance Sheet
Debt/Equity0.62
Current Ratio1.98
Quick Ratio1.02
Book Value/Sh8.569 GBp
Cash/Share1.335 GBp
Dividends
Fwd Div Rate0.6300 GBp
Trail. Div Rate0.8600 GBp
Div. Yield3.83%
5Y Avg Yield2.90%
Payout Ratio46.87%
Ex-Div DateAug 13, 2026
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1872.49 GBp
Upside (mean)+14.5%
Target Range1305.09 GBp – 2589.72 GBp
GBp1305.09+14.5% to meanGBp2589.72
# Analysts12
Ownership
Shares Out.207.23M
Float146.44M
Insiders32.91%
Institutions36.48%
Technical
SMA 501566.10 (+4.5%)
SMA 2001484.27 (+10.2%)
Beta0.66
S&P 52W Chg18.16%
Avg Vol (30d)968.53K
Avg Vol (10d)1.61M
Technical Indicators
RSI (14)52.8
MACD26.2098
MACD Signal27.8104
MACD Hist.-1.6006
BB Upper1706.98 GBp
BB Middle1617.11 GBp
BB Lower1527.25 GBp
BB Width11.11%
ATR (14)47.13 GBp
Vol Ratio (20d)0.40x